Overview:
• Under the radar companies
• Huge upside
• Difficult FDA approval behind them
⇒ Typical for drug device combo
⇒ 2 CRLs
• But still high risk/high reward stock
Details:
Single drug company
• Furoscix
⇒ SubQ furosemide via on body infusor
⇒ Diuretic for fluid build up in chronic heart failure
• Early commercial - Launched Feb ‘23
• Market opp $7B
Sales Pitch:
Large cost savings for Medicare & insurers
✔️Patients stay home instead of IV @ hospital
✔️Hospitals save $
⇒ Heart failure overstays & readmits cost them $
Financials look attractive:
• MC = $300M; EV = $243M
⇒ Lots of upside
⇒ Cash = 117M
⇒ Quart burn = $11M
Patent protection seems OK:
• thru 2034
• Methods of treating
• Formulations
• But, cannot patent active ingredient
Initial market response promising?
⇒ $2.2M Q1 (5 weeks only)
>50% increase in scripts in May vs. April
• Seems positioned well for future M&A if...
⇒ Revenue gets to $10s M/q
⇒ Based on rest of above facts
Summary:
SCPH is a high risk high reward opportunity
Proceed with caution
* Pricing info from Inside Rx
Article History:
Originally Published 7/17/23 (RB)
This is not investment, legal or tax advice. Do your own diligence and seek the advice of professionals.
Comments